Knowthestock.com
APVO - Aptevo Therapeutics, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

24%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -29.74%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -101.87%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.5
Debt Ratio is 0.53
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Aptevo Therapeutics, Inc. (APVO) - http://www.aptevotherapeutics.com
Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Marvin L. White
Employees - 80
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.